NEW YORK (GenomeWeb) – Muse Bio announced today that it has raised $23 million through an oversubscribed Series B financing round.
The round was led by Venrock and included Foresite Capital and Paladin Capital, as well as Series A investors NanoDimension and Spruce/MLS.
According to the company, the Series B funding will allow it to accelerate the commercialization of its ForgeCraft genome-editing technology. The technology is based on a multiplex version of CRISPR/Cas9 gene editing called CREATE — short for CRISPR/Cas9-enabled trackable genome engineering — combined with forward design software, proprietary reagents and algorithms, and an automated instrument.
"We are excited to be funded by this high-quality group of investors with a proven track record of success," Muse Bio CEO Kevin Ness said in a statement. "They recognize the value of Muse Bio's technology, which enables scientists to make multiple, clearly defined genomic modifications at any site within a cell's genome in a high-throughput and cost-effective manner."